Doximity, Inc. (DOCS) on Decifer

Decifer ranks DOCS number 138 of 277 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 17% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 13% a year and profits are expected to grow 11%.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power.
• and has the balance sheet to fund its growth.
• And it returns cash to shareholders.
• Strong returns around 17% with steady high margins are solid, but revenue growing about 13% a year, momentum of 0 out of 35, and no worldview role leave little to chase.

The current read

The evidence on DOCS lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Doximity, Inc. operates in medical - healthcare information services. That places it inside the Healthcare, Biotech & Devices story.

Read the full DOCS research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.